Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03724149 · ClinicalTrials.gov registry record · Phase 1
Transplanting Hepatitis C Lungs Into Negative Lung Recipients
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03724149: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT03724149 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03724149, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study is being conducted to determine safety and effectiveness of transplanting lungs from Hepatitis C-positive donors into Hepatitis C-negative patients on the lung transplant waitlist, who will then be treated with appropriate direct-acting antiviral (DAA) after transplantation.
Interventions
- DRUG Epclusa
- DRUG Zepatier
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03724149
The ClinicalTrials.gov registry entry for NCT03724149 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epclusa is the first listed.
NCT03724149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03724149 about?
NCT03724149 is a clinical study titled "Transplanting Hepatitis C Lungs Into Negative Lung Recipients". This study is being conducted to determine safety and effectiveness of transplanting lungs from Hepatitis C-positive donors into Hepatitis C-negative patients on the lung transplant waitlist, who will then be treated with appropriate direct-acting antiviral (DAA) after transplantation.
What is the current status of trial NCT03724149?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2018-12-12. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03724149?
The interventions under investigation include: Epclusa (DRUG), Zepatier (DRUG).
Who is sponsoring clinical trial NCT03724149?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.